greeksoup/ stock research
Stock research / United States / Funds / Opaleye Management Inc.

Opaleye Management Inc.

CIK 1595855 · latest 13F filed 14 August 2026 · Read the filing on EDGAR

Opaleye Management Inc. reported 58 US-listed holdings worth $1.10 billion in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Liquidia Corp. (17.7%), Eton Pharmaceuticals Inc. (9.4%) and Harrow Inc. (9.2%). Against the quarter before, it opened 13 positions, added to 15, trimmed 13 and sold out of 9.

Reported holdings$1.10B+45.4% on Q1 2026
Positions58+4 on Q1 2026
The largest ten64.8%of its reported holdings
Latest 13FQ2 2026filed 14 August 2026
Where the money is
OpenedAdded toHeldTrimmed
LQDA17.7%ETON9.4%HROW9.2%IRON5.7%URGN4.8%APGE4.7%MGTX4.3%SLGL3.4%RZLT3.0%TGTX2.7%IMMX2.2%CBIO2.2%STOK2.1%ACOG1.9%44 more26.9%

The 14 largest of its 58 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.

Reported holdings, quarter by quarter
Q3 2024: $591.4 million in 42 positions$591MQ3 24Q4 2024: $560.7 million in 37 positions$561MQ4 24Q1 2025: $438.3 million in 43 positions$438MQ1 25Q2 2025: $483.6 million in 39 positions$484MQ2 25Q3 2025: $702.7 million in 42 positions$703MQ3 25Q4 2025: $757.9 million in 54 positions$758MQ4 25Q1 2026: $759.2 million in 54 positions$759MQ1 26Q2 2026: $1.10 billion in 58 positions$1.10BQ2 26

What the fund reported holding at each quarter's end; hover a bar for the number of positions

What it did on the quarter

Opened 13Added 15Held 17Trimmed 13Sold out 9
Opened: 13Added: 15Held: 17Trimmed: 13Sold out: 9

Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held

Opened 13

  1. Immix Biopharma Inc. IMMX$24.2 million
  2. Monte Rosa Therapeutics Inc. GLUE$18.0 million
  3. Replimune Group, Inc. REPL$15.3 million
  4. Verastem Inc. VSTM$6.9 million
  5. Phathom Pharmaceuticals Inc. PHAT$2.0 million
  6. Inhibrx Biosciences Inc. INBX$1.9 million
  7. Hemab Therapeutics Hldgs Inc. COAG$1.8 million
  8. First Tracks Biotherapeutics TRAX$1.3 million

and 5 more in the table below

Added to 15

  1. Disc Medicine Inc. IRON+434,000 shares · +103%
  2. Meiragtx Holdings PLC MGTX+1.4 million shares · +67%
  3. Cabaletta Bio Inc. CABA+2.5 million shares · +180%
  4. Editas Medicine, Inc. EDIT+1.9 million shares · +100%
  5. Bridgebio Oncology Therapeutics Ord BBOT+646,718 shares · +1214%
  6. Lyell Immunopharma Inc. LYEL+264,928 shares · +335%
  7. 4D Molecular Therapeutics in FDMT+222,146 shares · +198%
  8. Alpha Cognition Inc. ACOG+333,517 shares · +13%

and 7 more in the table below

Trimmed 13

  1. Harrow Inc. HROW-432,230 shares · -15%
  2. Liquidia Corp. LQDA-97,500 shares · -4%
  3. Sanuwave Health Inc. SNWV-675,127 shares · -69%
  4. Jade Biosciences Inc. JBIO-282,608 shares · -66%
  5. CG Oncology Inc. CGON-77,011 shares · -81%
  6. Journey Medical Corp. (derm) DERM-610,000 shares · -64%
  7. Q32 Bio Inc. QTTB-325,228 shares · -26%
  8. Annexon Inc. ANNX-617,310 shares · -26%

and 5 more in the table below

Sold out of 9

  1. Perspective Therapeutics Inc CATX$19.5 million last quarter
  2. Assertio Hldgs Inc. ASRT$5.1 million last quarter
  3. Sutro Biopharma Inc. STRO$4.7 million last quarter
  4. Tectonic Therapeutic Inc. TECX$3.8 million last quarter
  5. Rigel Pharmaceuticals Inc. RIGL$1.9 million last quarter
  6. Nextcure Inc. NXTC$1.5 million last quarter
  7. Perspective Therapeutics Inc.$834,000 last quarter
  8. Protalix Biotherapeutics Inc. PLX$737,800 last quarter

What it holds

CompanySharesValueOf its bookChange in shares
Liquidia Corp. LQDA2,447,500$195.1 million17.67%-97,500
Eton Pharmaceuticals Inc. ETON2,860,000$103.5 million9.38%no change
Harrow Inc. HROW2,400,000$101.9 million9.23%-432,230
Disc Medicine Inc. IRON855,000$62.5 million5.66%+434,000
Urogen Pharma Ltd URGN1,439,996$53.0 million4.80%+9,996
Apogee Therapeutics Inc. APGE390,000$51.8 million4.69%no change
Meiragtx Holdings PLC MGTX3,550,000$48.0 million4.34%+1,426,741
Sol Gel Technologies SLGL500,000$37.1 million3.36%no change
Rezolute Inc. RZLT6,300,000$32.8 million2.97%no change
TG Therapeutics, Inc. TGTX535,000$29.4 million2.66%no change
Immix Biopharma Inc. IMMX2,345,000$24.2 million2.19%new
Crescent Biopharma Inc. CBIO1,319,351$23.7 million2.15%+6,736
Stoke Therapeutics Inc. STOK700,000$22.9 million2.07%no change
Alpha Cognition Inc. ACOG2,895,467$20.9 million1.89%+333,517
Edgewise Therapeutics Inc. EWTX500,000$20.3 million1.84%no change
Revolution Medicines, Inc. RVMD100,000$18.7 million1.70%no change
Monte Rosa Therapeutics Inc. GLUE745,000$18.0 million1.63%new
Alumis Inc. ALMS550,000$15.5 million1.40%no change
Codexis Inc. CDXS6,785,000$15.3 million1.39%no change
Replimune Group, Inc. REPL1,384,993$15.3 million1.39%new
Xoma Royalty Corporation XOMA338,374$14.4 million1.30%+38,374
MBX Biosciences Inc. MBX260,000$14.4 million1.30%no change
Rhythm Pharmaceuticals Inc. RYTM122,500$13.6 million1.23%-500
Editas Medicine, Inc. EDIT3,861,930$12.5 million1.13%+1,934,933
Protagonist Therapeutics, Inc. PTGX100,000$12.3 million1.11%no change
Cabaletta Bio Inc. CABA3,863,800$12.0 million1.09%+2,483,800
Q32 Bio Inc. QTTB931,000$11.9 million1.07%-325,228
Annexon Inc. ANNX1,714,451$9.8 million0.89%-617,310
Verastem Inc. VSTM1,800,000$6.9 million0.62%new
Zentalis Pharmaceuticals Inc. ZNTL1,412,656$6.9 million0.62%no change
Relmada Therapeutics Inc. RLMD935,000$6.5 million0.59%no change
Ocular Therapeutix Inc. OCUL600,000$5.9 million0.53%no change
Trevi Therapeutics Inc. TRVI310,000$5.8 million0.52%-35,100
Bridgebio Oncology Therapeutics Ord BBOT700,000$5.3 million0.48%+646,718
Lyell Immunopharma Inc. LYEL344,025$4.8 million0.44%+264,928
Ocuphire Pharma Inc. IRD1,125,000$4.6 million0.42%+5,000
4D Molecular Therapeutics in FDMT334,437$4.4 million0.40%+222,146
Intellia Therapeutics Inc. NTLA250,000$4.2 million0.38%+5,000
Voyager Therapeutics Inc. VYGR1,185,000$4.1 million0.38%+35,000
Biodesix Inc. BDSX180,000$4.1 million0.37%-58,047
Rocket Pharmaceuticals Inc. RCKT1,000,000$3.4 million0.31%+45,000
Jade Biosciences Inc. JBIO145,000$3.2 million0.29%-282,608
Sanuwave Health Inc. SNWV306,140$3.1 million0.28%-675,127
Fortress Biotech Inc. (fbio) FBIO890,000$2.7 million0.25%-152,000
Journey Medical Corp. (derm) DERM350,000$2.5 million0.22%-610,000
Phathom Pharmaceuticals Inc. PHAT185,589$2.0 million0.18%new
Inhibrx Biosciences Inc. INBX20,291$1.9 million0.17%new
Enanta Pharmaceuticals Inc. ENTA125,000$1.8 million0.17%no change
Hemab Therapeutics Hldgs Inc. COAG47,652$1.8 million0.16%new
First Tracks Biotherapeutics TRAX65,000$1.3 million0.12%new
CG Oncology Inc. CGON17,789$1.3 million0.11%-77,011
Biohaven Ltd BHVN77,915$1.2 million0.10%new
Atea Pharmaceuticals Inc. AVIR235,000$1.1 million0.10%-87,600
Pasithea Therapeutics Corp. KTTA2,050,000$1.1 million0.10%new
Auven Therapeutics Management ADCT700,000$749,0000.07%new
Okyo Pharma Ltd OKYO375,204$562,8060.05%new
Palatin Technologies Inc. PTNT20,500$221,1950.02%new
Adagio Med Hldgs Inc. ADGM18,444$13,3530.00%no change
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.
Read moreChange is shares against its 13F for the quarter before; the 9 it sold out of are in the box above.